ClinicalTrials.gov record
Completed Phase 3 Interventional

Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

ClinicalTrials.gov ID: NCT02108860

Public ClinicalTrials.gov record NCT02108860. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) (ABROGATE)

Study identification

NCT ID
NCT02108860
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
University of South Florida
Other
Enrollment
65 participants

Conditions and interventions

Eligibility (public fields only)

Age range
15 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 24, 2015
Primary completion
Jul 24, 2023
Completion
Dec 19, 2023
Last update posted
Jul 28, 2024

2015 – 2023

United States locations

U.S. sites
10
U.S. states
10
U.S. cities
10
Facility City State ZIP Site status
Cedars Sinai Medical Center, Los Angeles Los Angeles California 90048
University of South Florida Rheumatology Tampa Florida 33612
University of Kansas Medical Center Kansas City Kansas 66160
University of Michigan Ann Arbor Michigan 48109
Mayo Clinic Rochester Rochester Minnesota 55902
Hospital for Special Surgery New York New York 10021
Cleveland Clinic Cleveland Ohio 44195
Oregon Health & Science University Portland Oregon 97239
University of Pennsylvania Philadelphia Pennsylvania 19104
Vanderbilt University Nashville Tennessee 37240

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02108860, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 28, 2024 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02108860 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →